Home » Stocks » Incyte

Incyte Corporation (INCY)

Stock Price: $100.01 USD 0.06 (0.06%)
Updated Aug 5, 2020 10:01 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 21.74B
Revenue (ttm) 2.23B
Net Income (ttm) -191.07M
Shares Out 217.37M
EPS (ttm) -1.75
PE Ratio n/a
Forward PE 35.21
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $100.01
Previous Close $99.95
Change ($) 0.06
Change (%) 0.06%
Day's Open 100.00
Day's Range 99.88 - 101.00
Day's Volume 133,084
52-Week Range 62.48 - 110.37

More Stats

Market Cap 21.74B
Enterprise Value 20.20B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 217.37M
Float 183.51M
EPS (basic) -0.89
EPS (diluted) -1.75
FCF / Share -0.50
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.95M
Short Ratio 4.39
Short % of Float 3.59%
Beta 1.04
PE Ratio n/a
Forward PE 35.21
P/FCF Ratio n/a
PS Ratio 9.75
PB Ratio 11.08
Revenue 2.23B
Operating Income -184.82M
Net Income -191.07M
Free Cash Flow -107.63M
Net Cash 1.54B
Net Cash / Share 7.09
Gross Margin 39.94%
Operating Margin -8.29%
Profit Margin -8.00%
FCF Margin -4.83%
ROA -7.20%
ROE -18.69%
ROIC -13.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (21)

Buy 9
Overweight 0
Hold 12
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

$103.06*
(3.05% upside)
Low
79.0
Current: $100.01
High
124.0
Target: 103.06
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2,1591,8821,5361,10675451135529794.46170
Revenue Growth14.71%22.5%38.93%46.7%47.36%44.1%19.49%214.5%-44.4%-
Gross Profit2,0451,7881,4571,04872750835429794.46170
Operating Income422155-23616250.65-4.80-16.101.15-14314.05
Net Income447109-3131046.53-48.48-83.15-44.32-187-31.85
Shares Outstanding215212205188180168148130125122
Earnings Per Share2.050.51-1.530.540.03-0.29-0.56-0.34-1.49-0.26
EPS Growth301.96%--1700%------
Operating Cash Flow711336-92.9930589.4126.269.18-94.83-16297.94
Capital Expenditures-78.06-73.48-111-120-26.00-27.88-4.27-2.84-3.80-4.11
Free Cash Flow633263-20418463.41-1.624.91-97.67-16693.83
Cash & Equivalents2,1191,4391,171809722615510228297462
Total Debt50.8817.4324.00651620675662331316293
Net Cash / Debt2,0681,4221,147158102-60.40-152-103-19.27169
Assets3,4272,6462,3031,6391,007796630330329490
Liabilities8287206721,219836878823505556578
Book Value2,5981,9261,631419171-81.63-193-175-227-88.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Incyte Corporation
Country United States
Employees 1,456
CEO Hervé Hoppenot

Stock Information

Ticker Symbol INCY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INCY
IPO Date November 4, 1993

Description

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited. The company was founded in 1991 and is headquartered in Wilmington, Delaware.